Sleepiness

BOSTON — Treatment with an investigational combination of low-dose pramipexole and rasagiline led to less excessive daytime sleepiness and fewer adverse events compared with pramipexole alone in early Parkinson’s disease, research showed.

The FDA has approved Lumryz, an extended-release formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.

Aculys Pharma, Inc. announced the initiation of a phase 3 trial of pitolisant, a histamine H3 receptor antagonist/inverse agonist in those with excessive daytime sleepiness that is associated with obstructive sleep apnea syndrome.

Adults who reported taking frequent daily naps had greater risk for essential hypertension and stroke compared with those who never or rarely nap, researchers reported.

The FDA has granted tentative approval to Lumryz, a once-at-bedtime oral treatment for excessive daytime sleepiness or cataplexy in adults with narcolepsy, Avadel Pharmaceuticals announced in a press release.

ATLANTA — People who spend more time per day using wireless mobile devices are more likely to have a higher BMI, lower-quality sleep and other adverse health outcomes, according to a presenter at ENDO 2022.

Older adults who nap for more than an hour a day had a 40% higher risk for developing Alzheimer’s disease compared with those who napped less than an hour a day, researchers reported in Alzheimer’s & Dementia.

Losing an hour of sleep and “springing forward” for daylight saving time may negatively impact CV and brain health, according to a press release from the American Heart Association.

Lack of energy, forgetfulness and feeling sleepy are the most common symptoms adults with hypothyroidism face with “brain fog,” a phrase patients use to describe a type of cognitive dysfunction, according to a speaker.

Nearly one-third of Americans may lose sleep on election night, according to results of a survey commissioned by the American Academy of Sleep Medicine.